# CJC-1295 Dosage in Research: Studied Doses, Routes, and Half-Life

> CJC-1295 dosage as it appears in the literature: human PK studies used single subcutaneous doses of 30, 60, or 90 ug/kg, with a 5.8-8.1-day DAC half-life. Studied doses only, not human recommendations.

What was administered, to which species, by which route, and how long it persisted. These are reported research parameters, never a recommendation for human use of an unapproved compound.

## CJC-1295 Doses Used in Published Research

CJC-1295 dosage in the published record is narrow and entirely pharmacokinetic. Human PK studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram of body weight in healthy adults [1][3]. The GHRH-knockout mouse growth study used a fixed 2 micrograms per dose, given at 24-, 48-, or 72-hour intervals, with the once-daily schedule normalizing growth [4]. That is the extent of the controlled dosing literature.

The two human studies are worth distinguishing. The Teichman 2006 study administered 30 or 60 micrograms per kilogram and tracked the GH and IGF-1 response across single and multiple doses, establishing the 5.8-to-8.1-day half-life [1]. The Ionescu/Frohman 2006 study used 60 or 90 micrograms per kilogram and focused on whether the pulse pattern survived continuous stimulation [3]. Both are early-phase pharmacokinetic work in healthy volunteers — not efficacy trials, and not powered for long-term safety [1].

The fixed-microgram figures that circulate in community and clinic "protocols" — commonly 100 to 300 micrograms for no-DAC Modified GRF 1-29 or for CJC-1295/ipamorelin pairings — are not derived from controlled human trials [1]. This console reports the studied doses; it does not convert them into a human regimen. Where a research dose is given in micrograms per kilogram, that is a body-weight-scaled experimental quantity from a named study, not guidance.

## Route, reconstitution, and stability in research handling

Every human pharmacokinetic study of CJC-1295 administered the peptide by subcutaneous injection; early GRF(1-29) PK work also used the intravenous route [1]. Oral bioavailability is negligible because CJC-1295 is a peptide and would be digested rather than absorbed [2]. The subcutaneous route is what the route schematic on this page represents — a depot from which the conjugate enters circulation and binds albumin [2].

In laboratory handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; its four substitutions confer protease resistance and the DAC conjugation confers the multi-day duration [2]. The protease resistance is not incidental: native GHRH is cleaved by dipeptidylpeptidase-IV within minutes, and it is the D-Ala2 substitution that blocks that cleavage and lets the analog survive long enough for the albumin conjugation to matter [2]. These are descriptions of how the compound is handled in a research setting, not instructions for human use. CJC-1295 is not approved for human use anywhere, and nothing on this page should be read as a protocol.

## CJC-1295 half-life: 5.8-8.1 days (DAC) vs minutes-to-hours (no-DAC)

Half-life is the dimension that splits this compound in two. The DAC variant has an estimated half-life of 5.8 to 8.1 days in healthy adults, and IGF-1 elevation persisted up to 28 days after multiple doses [1]. That multi-day persistence is the direct consequence of covalent albumin binding — the conjugate clears at roughly the rate albumin does [2].

The no-DAC form, Modified GRF 1-29, is short-acting, in the minutes-to-hours range, reflecting native GHRH(1-29) clearance modified only by the protease-resistant substitutions [1]. This single difference is why the two forms have entirely different dosing logic and why the [DAC vs no-DAC half-life](/dac-vs-no-dac) page treats them as separate molecules. The human clinical data behind all of these numbers is limited: early-phase PK studies in healthy volunteers established the GH/IGF-1 kinetics, the ConjuChem Phase 2 program was discontinued, and there are no large efficacy or long-term safety trials [1].

## How much CJC-1295 should I take?

Human PK studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram in healthy adults; community "protocols" citing fixed 100-to-300-microgram doses are not derived from controlled human trials [1][3]. This site reports studied doses, not human recommendations, and CJC-1295 is an unapproved research chemical.

## How much CJC-1295 DAC should I take?

The DAC variant's multi-day half-life of 5.8 to 8.1 days is why its dosing schedule differs fundamentally from the short-acting no-DAC form [1]. Published human PK work used 30-to-90-microgram-per-kilogram single subcutaneous doses [1][3]. No human dose is endorsed here; the half-life is reported because it is the parameter that governs how the compound was studied.

## How to reconstitute CJC-1295?

In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide [2]. These handling notes describe laboratory practice, not human-use instructions, and CJC-1295 is not approved for human use.

## Where to inject CJC-1295?

Published pharmacokinetic studies administered CJC-1295 by subcutaneous injection [1]. This describes the route used in research and is not guidance for human use of an unapproved compound.

---

A research console that reads the published CJC-1295 record straight — basal GH, IGF-1, and the DAC-versus-no-DAC half-life logged to source and tagged by evidence strength, with no clinic behind the console and no script filled here.